Multiplication

Multiply Labs and Wilson Wolf Corporation Collaborate to Automate G-Rex® Bioreactor for Cell Therapy Manufacturing

Retrieved on: 
Thursday, May 2, 2024
Software, Research, General Health, Hardware, Robotics, Technology, Other Manufacturing, Clinical Trials, Science, Engineering, Health, Other Science, Manufacturing, International Society, Multiplication, Automation, Cell, Partnership, CGT, Entrepreneurship, Patient, ISCT, Movement, Nutrient, GMP, Cytotherapy, Organization, Fine chemical

Multiply Labs , a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, and Wilson Wolf , an innovative leader in cell and gene-modified cell (CGT) manufacturing technology, today announced a collaboration around the automation of Wilson Wolf’s G-Rex ® bioreactors.

Key Points: 
  • Multiply Labs , a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, and Wilson Wolf , an innovative leader in cell and gene-modified cell (CGT) manufacturing technology, today announced a collaboration around the automation of Wilson Wolf’s G-Rex ® bioreactors.
  • The ultimate goal is to lower the barriers to widespread accessibility of potentially lifesaving cell and gene therapy drug products.
  • "Our partnership with Wilson Wolf will be pivotal in realizing this future, as their G-Rex® bioreactors are extensively used for cell therapy manufacturing today.
  • Industry estimates suggest this technology could cut typical GMP-level cell therapy manufacturing costs by around 70% per product.

Multiply Labs Announces Upcoming Collaboration with Stanford Medicine’s Laboratory for Cell and Gene Medicine (LCGM) to Deploy Automated Systems For Cell Therapy Manufacturing

Retrieved on: 
Tuesday, April 23, 2024
Biotechnology, Pharmaceutical, Other Manufacturing, Health, Robotics, Technology, Genetics, Manufacturing, Multiplication, Cell, Automation, Patient, GMP, Organization, Medical device

Multiply Labs , a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, today announced its upcoming collaboration with Stanford Medicine’s Laboratory for Cell & Gene Medicine (LCGM) to demonstrate the potential of automation technology for cell therapy manufacturing.

Key Points: 
  • Multiply Labs , a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, today announced its upcoming collaboration with Stanford Medicine’s Laboratory for Cell & Gene Medicine (LCGM) to demonstrate the potential of automation technology for cell therapy manufacturing.
  • This collaboration will combine LCGM’s world-leading process development expertise with Multiply Labs’ robotic technology.
  • Multiply Labs’ unique approach to cell therapy manufacturing automation focuses on robotic systems that can operate GMP-proven instruments from multiple different vendors.
  • This aligns directly with Multiply Labs’ mission to enhance patient access to life-saving cell therapies by scaling availability through automation.

Multiply Labs Unveils First Peer-Reviewed Study Showing that Robotic Cell Expansion Can Match the Performance and Reduce the Costs of a Manual Process

Retrieved on: 
Tuesday, March 26, 2024
Biotechnology, Pharmaceutical, Other Manufacturing, Health, Robotics, Health Technology, Technology, Manufacturing, Automation, Multiplication, Patient, GMP, Cell, Multimedia, Therapy, Organization, ISCT, FDA, Phenotype, International Society, Medical device

View the full release here: https://www.businesswire.com/news/home/20240326888217/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240326888217/en/
    The paper, “ Development of a robotic cluster for automated and scalable cell therapy manufacturing ,” found that during the expansion phase of T cells-based therapy, Multiply Labs’ robotic system can automate an existing manual process while maintaining statistical equivalence on all critical process parameters.
  • In fact, as much as 50% of manufacturing costs stem from labor-intensive manual processes and a shortage of skilled workers.
  • A key advantage of Multiply Labs’ robotic technology is its compatibility with leading cell therapy manufacturing instruments.
  • The data in this study shows that it is possible to automate an existing cell expansion protocol without significantly changing the process or impacting product characteristics.

Impartner Announces Winners of the Partnership Excellence Awards

Retrieved on: 
Tuesday, February 13, 2024
Vertiv, Partnership, Goto, Customer advisory council, Organization, Multiplication, PRM

SALT LAKE CITY, Feb. 13, 2024 /PRNewswire/ -- Impartner, the world's most complete, most highly rated, and most award-winning Partner Relationship Management (PRM) provider, is thrilled to announce the 2023 Partnership Excellence Awards recipients. The awards ceremony took place at Multiply: ImpartnerCon '24, a one-of-a-kind gathering where innovation, collaboration, and inspiration come together to redefine the future of partnerships. The annual conference drew 400+ attendees from around the globe.

Key Points: 
  • Impartner unveils the Partnership Excellence Awards recipients, celebrating unparalleled innovation and dedication in partner relationship management, at Multiply: ImpartnerCon '24.
  • SALT LAKE CITY, Feb. 13, 2024 /PRNewswire/ -- Impartner , the world's most complete, most highly rated, and most award-winning Partner Relationship Management (PRM) provider, is thrilled to announce the 2023 Partnership Excellence Awards recipients.
  • The awards ceremony took place at Multiply: ImpartnerCon '24 , a one-of-a-kind gathering where innovation, collaboration, and inspiration come together to redefine the future of partnerships.
  • The Impartner Partnership Excellence Awards recognize individuals and organizations who have achieved remarkable success, demonstrated industry-changing innovation, and shown unwavering dedication to partnership excellence.

Impartner's Ryan Knapp Honored as a 2024 CRN® Channel Chief

Retrieved on: 
Tuesday, February 6, 2024
Growth, Churn, Editing, PRM, CRN, Multiplication, The Channel Company, Management

SALT LAKE CITY, Feb. 6, 2024 /PRNewswire/ -- Impartner, the world's most complete, most highly rated, and most award-winning Partner Relationship Management (PRM) provider, is proud to announce CRN®, a brand of The Channel Company, has recognized Ryan Knapp, Global Head of Partnerships, on its 2024 Channel Chiefs list for the first time. Each year, this exclusive roster pays tribute to accomplished channel leaders whose relentless efforts drive forward the channel agenda, crafting and executing highly successful channel partner programs and strategies. Knapp is celebrated today at Multiply: ImpartnerCon '24 in Miami, FL, for showcasing his exceptional achievements and innovative business strategy with this industry recognition.

Key Points: 
  • SALT LAKE CITY, Feb. 6, 2024 /PRNewswire/ -- Impartner , the world's most complete, most highly rated, and most award-winning Partner Relationship Management (PRM) provider, is proud to announce CRN ®, a brand of The Channel Company , has recognized Ryan Knapp , Global Head of Partnerships, on its 2024 Channel Chiefs list for the first time.
  • Each year, this exclusive roster pays tribute to accomplished channel leaders whose relentless efforts drive forward the channel agenda, crafting and executing highly successful channel partner programs and strategies.
  • "As we launch into 2024, constructing and leveraging a partner ecosystem has never been more important," said Knapp.
  • The Channel Company is pleased to acknowledge these prominent channel leaders and looks forward to chronicling their achievements throughout the year."

Impartner Announces Rod Baptie, CEO of Channel Focus, as a Keynote Speaker for Multiply: ImpartnerCon '24 Alongside Industry Visionaries

Retrieved on: 
Tuesday, January 16, 2024
Senior, Spur, JSG, Business, PRM, Partner, Digital, Telecom, LIVE, Salesforce, Secrecy, Multiplication, TD SYNNEX, Marketing, Management

SALT LAKE CITY, Jan. 16, 2024 /PRNewswire/ -- Impartner, the fastest-growing and most award-winning industry-leading provider of reseller and partner management technologies, announced the addition of Rod Baptie, CEO of Channel Focus as a keynote speaker for Multiply: ImpartnerCon '24, bringing a wealth of industry knowledge and leadership. Additionally, new speakers and sessions have been released featuring leaders from Palo Alto Networks, Smartsheet, Itron, and more.

Key Points: 
  • Impartner is thrilled to join forces with Channel Focus, a global authority in delivering best practice and how-to insights for the IT and Telecom channel industry, alongside a star-studded speaker roster at ImpartnerCon 2024.
  • SALT LAKE CITY, Jan. 16, 2024 /PRNewswire/ -- Impartner , the fastest-growing and most award-winning industry-leading provider of reseller and partner management technologies, announced the addition of Rod Baptie, CEO of Channel Focus as a keynote speaker for Multiply: ImpartnerCon '24 , bringing a wealth of industry knowledge and leadership.
  • Additionally, new speakers and sessions have been released featuring leaders from Palo Alto Networks, Smartsheet, Itron, and more.
  • Rod Baptie has played a pivotal role in the hi-tech sector, overseeing the successful launch of over 20 major technology companies.

Multiply Labs and Fedegari Group Collaborate to Add Sterilization to Automated Cell Therapy Manufacturing for Eliminating Contamination Risks

Retrieved on: 
Tuesday, January 9, 2024
Software, Machinery, Hardware, Pharmaceutical, Robotics, Technology, Other Manufacturing, Health Technology, Science, Biotechnology, Health, Other Science, Manufacturing, Risk, Entrepreneurship, Sterilization, Multimedia, Partnership, Decontamination, Automation, Multiplication, MD, VHP, Medical device

Leveraging Multiply Labs' cell therapy robotic cluster and Fedegari’s sterilization and bio-decontamination technology, this partnership will effectively reduce any contamination risk by automating sterilization capabilities.

Key Points: 
  • Leveraging Multiply Labs' cell therapy robotic cluster and Fedegari’s sterilization and bio-decontamination technology, this partnership will effectively reduce any contamination risk by automating sterilization capabilities.
  • View the full release here: https://www.businesswire.com/news/home/20240109079120/en/
    Multiply Labs and Fedegari Group announced a strategic partnership around the automation of the sterilization of cell therapy robotic systems.
  • To solve for this, Multiply Labs and Fedegari will collaborate to develop an automated decontamination unit to serve as the input and output module for robotic cell therapy manufacturing.
  • “As we relentlessly pursue Multiply Labs’ goal of introducing a fully automated, end-to-end cell therapy manufacturing process to the market, our partnership with Fedegari marks a pivotal stride toward this vision.”

Multiply Labs Releases Preprint Data Showing That Automated and Manual Cell Expansion Processes Are Statistically Equivalent

Retrieved on: 
Friday, January 5, 2024
Research, Pharmaceutical, Robotics, Technology, Other Manufacturing, Science, Engineering, Biotechnology, Other Technology, Manufacturing, Other Science, Health, Multimedia, FDA, Staphylococcus epidermidis, Thermo Fisher Scientific, GMP, Gene, Charles River Laboratories, Multiplication, Therapy, Automation, Cell, UCSF, Skin

This data demonstrates that automated cell therapy manufacturing outcomes (cell quantity and quality) using Multiply Labs’ proof-of-concept robotic system are statistically equivalent to that of a process performed manually.

Key Points: 
  • This data demonstrates that automated cell therapy manufacturing outcomes (cell quantity and quality) using Multiply Labs’ proof-of-concept robotic system are statistically equivalent to that of a process performed manually.
  • “This data demonstrates that manufacturers can confidently automate their existing processes for cell expansion, without making significant modifications to the process itself, effectively minimizing bioprocess and regulatory risks.
  • In addition to cell count and viability successes, none of the robotic cell expansion samples were contaminated.
  • The research, titled “Development of a robotic cluster for automated and scalable cell therapy manufacturing,” is currently under review.

Neuchips to Showcase Industry-Leading Gen AI Inferencing Accelerators at CES 2024

Retrieved on: 
Tuesday, January 2, 2024
Raptor, HHHL, Personal, ASIC, Vector, Whispering, Natural language processing, Electricity, Viperidae, LLM, AI, Matrix, TERA, PCI Express, Multiplication, LPDDR5, CES, Memory, Acceleration

LAS VEGAS, Nev., Jan. 2, 2024 /PRNewswire/ -- Neuchips , a leading AI Application-Specific Integrated Circuits (ASIC) solutions provider, will demo its revolutionary Raptor Gen AI accelerator chip (previously named N3000) and Evo PCIe accelerator card LLM solutions at CES 2024.

Key Points: 
  • LAS VEGAS, Nev., Jan. 2, 2024 /PRNewswire/ -- Neuchips , a leading AI Application-Specific Integrated Circuits (ASIC) solutions provider, will demo its revolutionary Raptor Gen AI accelerator chip (previously named N3000) and Evo PCIe accelerator card LLM solutions at CES 2024.
  • "We are thrilled to unveil our Raptor chip and Evo card to the industry at CES 2024," said Ken Lau, CEO of Neuchips.
  • With Neuchips, any organisation can now access the power of LLMs for a wide range of AI applications."
  • At CES 2024, Neuchips will demo Raptor and Evo, accelerating the Whisper and Llama AI chatbots on a Personal AI Assistant application.

Multiply Labs and Akron Bio Partner to Automate the Use of cGMP-Compliant Liquid Cytokines in Cell Therapy Manufacturing

Retrieved on: 
Wednesday, December 20, 2023
Biotechnology, Pharmaceutical, Other Manufacturing, Health, Robotics, Health Technology, Technology, Manufacturing, Entrepreneurship, Cytokine, Partnership, Risk, Multimedia, Workflow, Syringe, Doctor of Philosophy, GMP, Multiplication, Rhu, Patient, Corporate development, Corporation, Fine chemical

View the full release here: https://www.businesswire.com/news/home/20231219192070/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231219192070/en/
    Multiply Labs' cell therapy robotics system.
  • (Photo: Business Wire)
    Leveraging Multiply Labs' cell therapy robotic cluster, this partnership will enable Akron’s cytokines, starting with cGMP-compliant rHu Interleukin-2 (IL-2) , to be automated with the use of robotics.
  • Multiply Labs’ robotic systems will incorporate Akron’s liquid IL-2 into its cell therapy manufacturing workflow in an aseptic manner, precisely formulating and dispensing the right amount for any given process.
  • “Our partnership with Multiply Labs will allow us to integrate Akron’s cGMP materials into cell therapy manufacturing workflows - simplifying delivery and reducing risk to patients.”
    Akron and Multiply Labs will partner to integrate Akron’s existing cGMP-compliant cytokines with Multiply Labs’ proprietary adapter system, thereby making these materials compatible with Multiply Labs’ cell therapy robotic clusters.